Influence of selected drugs used in pharmacotherapy of cardiovascular disorders on the function of the gastrointestinal tract Review article
Article Sidebar
Main Article Content
Abstract
Drugs used in pharmacotherapy of cardiovascular disorders are one of the most commonly used medical products. In this article we present actual knowledge considering the influence of statins, bile acid sequestrants and angiotensin-converting-enzyme inhibitors (ACE-I) on the function of the gastrointestinal tract. Present data considering efficacy and safety of abovementioned drugs either do not contain information considering their influence on the function of the gastrointestinal tract, or information are incomplete. However, during usage of most of those drugs adverse effects, such as diarrhoea or constipation, do occur. Frequency and intensity of those adverse effects is slightly higher than in placebo controls. Sporadically some of those drugs cause nausea, vomiting or flatulence. It is hard to determine frequency of flatulence basing on literature data, but it is described in some works as an adverse effect. The only drug that causes frequent flatulence in a lot of patients is acetylsalicylic acid administered in its enteral form, administered in doses used in prevention of cardiovascular disorders.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Kang S., Liu Y., Liu X.B.: Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials. Clin. Ther. 2013; 35: 1125-1136.
3. Braamskamp M.J., Kusters D.M., Avis H.J. et al.: Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Pediatr. Drugs 2015; 17: 159-166.
4. Muscari A., Puddu G.M., Puddu P.: Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002; 97: 115-121.
5. Bakker-Arkema R.G., Nawrocki J.W., Black D.M.: Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 2000; 149: 123-129.
6. Davidson M.: The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin. Ther. 2013; 35: 1247-1252.
7. Dohmen H.J.M., Dunselman P.H., Poole-Wilson P.A.: Comparison of captopril and ibopamine in mild to moderate heart failure. Heart 1997; 78: 285-290.
8. Edwards I.R., Coulter D.M., Beasley D.M., MacIntosh D.: Captopril: 4 years of post marketing surveillance of all patients in New Zealand. Br. J. Clin. Pharmacol. 1987; 23: 529-536.
9. Edwards I.R., Coulter D.M., Macintosh D.: Intestinal effects of captopril. BMJ 1992; 304: 359-360.
10. Guay D.R.F.: Trandolapil: a newer angiotensin-converting enzyme inhibitor. Clin. Ther. 2003; 25: 713-775.
11. Stirling C., Houston J.: Diarrhoea, vomiting and ACE inhibitors – an important cause of acute renal failure. J. Human Hypertens. 2003; 17: 419-423.
12. Benson B.C., Smith C., Laczek J.T.: Angiotensin converting enzyme inhibitor-induced gastrointestinal angioedema. A case series and literature review. J. Clin. Gastroenterol. 2013; 47: 844-849.
13. Turcu A.F., White J.A., Kulaga M.E. et al.: Calcium channel blocker-associated small bowel angioedema. J. Clin. Gastroenterol. 2009; 43: 338-341.
14. Stacey R., Green J.T.: Radiation-induced small bowel disease: latest developments and clinical guidance. Ther. Adv. Chronic. Dis. 2014; 5(1): 15-29.
15. Sipahi I., Chou J., Mishra P. et al.: Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am. J. Cardiol. 2011; 108(2): 294-301.
16. Cardwell C.R., Mc Menamin Ú.C., Hicks B.M. et al.: Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Medicine 2014; 12: 28.
17. Makar G.A., Holmes J.H., Yang Y.X.: Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J. Natl. Cancer Inst. 2014; 106(2): 1-8.
18. Focks J.J., Tielemans M.M., van Rossum L.G. et al.: Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth. Heart J. 2014; 22: 107-112.